Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-05-15 | Reverse | 1:10 |
| 2014-08-01 | Reverse | 1:3 |
Burning Rock Biotech Limited develops and offers NGS-based cancer therapy tests in China, covering various cancers with collaborations and licensed products for personalized diagnosis and treatment.

Burning Rock's companion diagnostic system uses next-generation sequencing to detect gene alterations in breast cancer, identifying patients for AstraZeneca's capivasertib and fulvestrant, with recent Japan approval advancing its global strategy.
| Icon | PRODUCT | Q2-2022 | Q4-2022 |
|---|---|---|---|
![]() | Service | $185.58M | $205.97M ▲ |
![]() | Product | $80.79M | $90.9M ▲ |
| Map | REGION | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
![]() | CHINA | $553.3M | $534.93M ▼ | $510.24M ▼ |
![]() | UNITED STATES | — | $2.51M | $5.58M ▲ |
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
AYTU | $2.25 | COMPARE |
PMN | $13.79 | COMPARE |
ADVB | $9.70 | COMPARE |
CODX | $1.21 | COMPARE |
AEMD | $2.49 | COMPARE |
PRPH | $0.02 | COMPARE |
NVNO | $10.75 | COMPARE |